RA Capital Management
Investor profile
Deals
10
distinct rounds
Companies
10
backed
Active span
2018–2025
8 yrs
Total round €
€1.6B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Andera Partners2
- Deep Track Capital2
- Forbion2
- Invus2
- AbbVie Ventures1
- Access Biotechnology1
- Adage Capital Management1
- Avidity Partners1
- Avoro Capital Advisors1
- CaaS Capital Management1
- Casdin Capital1
- CureDuchenne Ventures1
- Deerfield1
- Droia Ventures1
- EcoR1 Capital1
- EQT Life Sciences1
- Fairmount1
- Fidelity Management & Research Company LLC1
- General Atlantic1
- Gray’s Creek Capital Partners1
- HealthCap1
- INKEF Capital1
- IP Group PLC1
- Janus Henderson Investors1
- Laurion Capital Management1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Bicycle Therapeutics | UK | 1 | €513M |
| Verdiva Bio | UK | 1 | €399M |
| Artios | UK | 1 | €199M |
| Hemab Therapeutics | Denmark | 1 | €127M |
| Pepgen | UK | 1 | €96M |
| T-knife | Germany | 1 | €94M |
| Ambagon Therapeutics | Netherlands | 1 | €75M |
| Alchemab Therapeutics | UK | 1 | €69M |
| Nucleix | Israel | 1 | €46M |
| Whiteswell | Ireland | 1 | €26M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Bicycle Therapeutics | Other | €513M | 2024-05 |
| Verdiva Bio | Series A | €399M | 2025-01 |
| Hemab Therapeutics | Series B | €127M | 2023-02 |
| Artios | Series D+ | €99M | 2025-11 |
| Artios | Series D+ | €99M | 2025-11 |
| Pepgen | Other | €96M | 2021-08 |
| T-knife | Series B | €94M | 2021-08 |
| Ambagon Therapeutics | Series A | €75M | 2022-01 |
| Alchemab Therapeutics | Series A | €69M | 2021-04 |
| Nucleix | Other | €46M | 2021-04 |